{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:25:19Z","timestamp":1791473119918,"version":"4.3.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA0911600"],"award-info":[{"award-number":["2021YFA0911600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The chemotherapy resistance is an awkward challenge in management of bladder cancer (BC). Cancer organoid model is an effective preclinical tumor model that could faithfully represent clinical manifestations and simulate the biological processes of chemoresistance. Recent studies have revealed that cancer stem cells (CSCs) play a significant role in the development of chemoresistance in cancer. Exosomes act as essential intercellular messengers and participate in controlling the conversion of distinct cell characteristics, including chemoresistance. However, the role of exosome-transmitted lncRNAs in bladder cancer chemoresistance has rarely been reported. In this study, cancer organoid models were developed from urothelial carcinomas to explore the pathophysiology mechanism of BC chemoresistance, and RNA-seq was performed to screen for lncRNAs involved in chemoresistance of BC. We found chemotherapy enriches stem-like cells in BC, and significant upregulation of Lung Cancer Associated Transcript 1 (LUCAT1) occurs in chemotherapy-resistant organoids and correlated with chemotherapy response. Further experimental results demonstrated that LUCAT1 promotes chemoresistance in bladder cancer by enhancing the stemness phenotype of BC cells in vivo and in vitro. Moreover, exosomes derived from bladder cancer stem cells can enhance the stemness phenotype and chemoresistance of BC cells by delivering LUCAT1. Mechanistically, LUCAT1 could significantly enhance the mRNA stability of HMGA1 via binding to IGF2BP2 in an m6A-dependent manner. The study demonstrates an important role for exosome-transmitted LUCAT1 in chemoresistance and LUCAT1 has the potential to function as both a diagnostic biomarker and therapeutic target for BC.<\/jats:p>","DOI":"10.1186\/s13046-025-03330-w","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T02:18:01Z","timestamp":1740968281000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Exosome-transmitted LUCAT1 promotes stemness transformation and chemoresistance in bladder cancer by binding to IGF2BP2"],"prefix":"10.1186","volume":"44","author":[{"given":"Yonghao","family":"Zhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaowei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianghao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuanbao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuepei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"issue":"1","key":"3330_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, et al. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3330_CR2","first-page":"64","volume":"11","author":"H Zi","year":"2024","unstructured":"Zi H, et al. Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021. Mil Med Res. 2024;11(1):64.","journal-title":"Mil Med Res"},{"issue":"1","key":"3330_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, et al. European association of urology guidelines on Muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82\u2013104.","journal-title":"Eur Urol"},{"key":"3330_CR4","doi-asserted-by":"crossref","unstructured":"Scilipoti P et al. The Financial Burden of Localized and Metastatic Bladder Cancer. Eur Urol, 2024.","DOI":"10.1016\/j.eururo.2024.12.002"},{"issue":"3","key":"3330_CR5","first-page":"221","volume":"46","author":"RS Zheng","year":"2024","unstructured":"Zheng RS, et al. [Cancer incidence and mortality in China, 2022]. Zhonghua Zhong Liu Za Zhi. 2024;46(3):221\u201331.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"19","key":"3330_CR6","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles T, et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder Cancer. N Engl J Med. 2024;391(19):1773\u201386.","journal-title":"N Engl J Med"},{"issue":"5","key":"3330_CR7","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3322\/caac.21631","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70(5):404\u201323.","journal-title":"CA Cancer J Clin"},{"key":"3330_CR8","doi-asserted-by":"crossref","unstructured":"St-Laurent MP, et al. Increasing life expectancy in patients with genitourinary malignancies: impact of treatment burden on disease management and quality of life. Eur Urol; 2024.","DOI":"10.1016\/j.eururo.2024.11.026"},{"key":"3330_CR9","doi-asserted-by":"publisher","first-page":"101116","DOI":"10.1016\/j.drup.2024.101116","volume":"76","author":"J Guo","year":"2024","unstructured":"Guo J, et al. A distinct subset of urothelial cells with enhanced EMT features promotes chemotherapy resistance and cancer recurrence by increasing COL4A1-ITGB1 mediated angiogenesis. Drug Resist Updat. 2024;76:101116.","journal-title":"Drug Resist Updat"},{"issue":"10","key":"3330_CR10","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/0008-5472.CAN-22-2213","volume":"83","author":"J Zhuang","year":"2023","unstructured":"Zhuang J, et al. Cancer-Associated Fibroblast-Derived miR-146a-5p generates a niche that promotes bladder Cancer stemness and chemoresistance. Cancer Res. 2023;83(10):1611\u201327.","journal-title":"Cancer Res"},{"issue":"7","key":"3330_CR11","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1158\/1078-0432.CCR-20-3946","volume":"27","author":"SJ Crabb","year":"2021","unstructured":"Crabb SJ, et al. Phase I trial of DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine for solid malignancies including urothelial carcinoma (SPIRE). Clin Cancer Res. 2021;27(7):1882\u201392.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3330_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s13046-024-03224-3","volume":"43","author":"L Zheng","year":"2024","unstructured":"Zheng L, et al. The KLF16\/MYC feedback loop is a therapeutic target in bladder cancer. J Exp Clin Cancer Res. 2024;43(1):303.","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"3330_CR13","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.ccell.2024.11.001","volume":"42","author":"X Wu","year":"2024","unstructured":"Wu X, Sheng X. Molecular subtyping in urothelial carcinoma treatment. Cancer Cell. 2024;42(12):1993\u20136.","journal-title":"Cancer Cell"},{"issue":"1","key":"3330_CR14","doi-asserted-by":"publisher","first-page":"100552","DOI":"10.1016\/j.medj.2024.11.005","volume":"6","author":"S Slavin","year":"2025","unstructured":"Slavin S. Cell-mediated immunotherapy: A new frontier in preventing disease progression and treating drug-resistant cancer. Med. 2025;6(1):100552.","journal-title":"Med"},{"key":"3330_CR15","doi-asserted-by":"publisher","first-page":"101084","DOI":"10.1016\/j.drup.2024.101084","volume":"74","author":"H Zhao","year":"2024","unstructured":"Zhao H, et al. Potential targets and therapeutics for cancer stem cell-based therapy against drug resistance in hepatocellular carcinoma. Drug Resist Updat. 2024;74:101084.","journal-title":"Drug Resist Updat"},{"issue":"8","key":"3330_CR16","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.stem.2024.06.003","volume":"31","author":"PE Saw","year":"2024","unstructured":"Saw PE, et al. Cancer stem cell mimicry for immune evasion and therapeutic resistance. Cell Stem Cell. 2024;31(8):1101\u201312.","journal-title":"Cell Stem Cell"},{"issue":"48","key":"3330_CR17","doi-asserted-by":"publisher","first-page":"eadh1891","DOI":"10.1126\/sciadv.adh1891","volume":"9","author":"J Cui","year":"2023","unstructured":"Cui J, et al. Targeting ABCA12-controlled ceramide homeostasis inhibits breast cancer stem cell function and chemoresistance. Sci Adv. 2023;9(48):eadh1891.","journal-title":"Sci Adv"},{"issue":"8","key":"3330_CR18","doi-asserted-by":"publisher","first-page":"E968","DOI":"10.1073\/pnas.1521230113","volume":"113","author":"J Kowal","year":"2016","unstructured":"Kowal J, et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci U S A. 2016;113(8):E968\u201377.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7964","key":"3330_CR19","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41586-023-06114-4","volume":"618","author":"G Wang","year":"2023","unstructured":"Wang G, et al. Tumour extracellular vesicles and particles induce liver metabolic dysfunction. Nature. 2023;618(7964):374\u201382.","journal-title":"Nature"},{"issue":"12","key":"3330_CR20","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1016\/j.cell.2022.04.016","volume":"185","author":"MR Puno","year":"2022","unstructured":"Puno MR, Lima CD. Structural basis for RNA surveillance by the human nuclear exosome targeting (NEXT) complex. Cell. 2022;185(12):2132\u2013e214726.","journal-title":"Cell"},{"issue":"8","key":"3330_CR21","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.cell.2023.03.010","volume":"186","author":"R Kalluri","year":"2023","unstructured":"Kalluri R, McAndrews KM. The role of extracellular vesicles in cancer. Cell. 2023;186(8):1610\u201326.","journal-title":"Cell"},{"issue":"2","key":"3330_CR22","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.cmet.2024.11.013","volume":"37","author":"Y Bi","year":"2025","unstructured":"Bi Y, et al. Exosomal miR-302b rejuvenates aging mice by reversing the proliferative arrest of senescent cells. Cell Metab. 2025;37(2):527\u201341. e6.","journal-title":"Cell Metab"},{"issue":"1","key":"3330_CR23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s13046-024-03204-7","volume":"43","author":"Y Liang","year":"2024","unstructured":"Liang Y, et al. Exosomal miR-106a-5p from highly metastatic colorectal cancer cells drives liver metastasis by inducing macrophage M2 polarization in the tumor microenvironment. J Exp Clin Cancer Res. 2024;43(1):281.","journal-title":"J Exp Clin Cancer Res"},{"key":"3330_CR24","doi-asserted-by":"crossref","unstructured":"Cai ZR et al. Construction of exosome non-coding RNA feature for non-invasive, early detection of gastric cancer patients by machine learning: a multi-cohort study. Gut, 2025.","DOI":"10.1136\/gutjnl-2024-333522"},{"issue":"1","key":"3330_CR25","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/s41467-025-56498-2","volume":"16","author":"Y Teng","year":"2025","unstructured":"Teng Y, et al. Plant-nanoparticles enhance anti-PD-L1 efficacy by shaping human commensal microbiota metabolites. Nat Commun. 2025;16(1):1295.","journal-title":"Nat Commun"},{"issue":"1","key":"3330_CR26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12943-024-01979-z","volume":"23","author":"Z He","year":"2024","unstructured":"He Z, et al. Exosomal long non-coding RNA TRPM2-AS promotes angiogenesis in gallbladder cancer through interacting with PABPC1 to activate NOTCH1 signaling pathway. Mol Cancer. 2024;23(1):65.","journal-title":"Mol Cancer"},{"key":"3330_CR27","doi-asserted-by":"crossref","unstructured":"Xu C et al. An exosome-based liquid biopsy predicts depth of response and survival outcomes to cetuximab and panitumumab in metastatic colorectal cancer: the EXONERATE study. Clin Cancer Res, 2025.","DOI":"10.1158\/1078-0432.CCR-24-1934"},{"issue":"1","key":"3330_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13046-025-03288-9","volume":"44","author":"Y Shen","year":"2025","unstructured":"Shen Y, et al. GC-derived Exosomal circMAN1A2 promotes cancer progression and suppresses T-cell antitumour immunity by inhibiting FBXW11-mediated SFPQ degradation. J Exp Clin Cancer Res. 2025;44(1):24.","journal-title":"J Exp Clin Cancer Res"},{"key":"3330_CR29","doi-asserted-by":"publisher","first-page":"122887","DOI":"10.1016\/j.biomaterials.2024.122887","volume":"314","author":"H Yang","year":"2025","unstructured":"Yang H, et al. ROS-responsive injectable hydrogels loaded with exosomes carrying miR-4500 reverse liver fibrosis. Biomaterials. 2025;314:122887.","journal-title":"Biomaterials"},{"issue":"10","key":"3330_CR30","doi-asserted-by":"publisher","first-page":"7644","DOI":"10.1021\/acsnano.4c00699","volume":"18","author":"H Zhang","year":"2024","unstructured":"Zhang H, et al. Iron oxide nanoparticles engineered Macrophage-Derived exosomes for targeted pathological angiogenesis therapy. ACS Nano. 2024;18(10):7644\u201355.","journal-title":"ACS Nano"},{"issue":"5","key":"3330_CR31","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.1021\/acsnano.3c09721","volume":"18","author":"X Jiang","year":"2024","unstructured":"Jiang X, et al. Highly bioactive MXene-M2-Exosome nanocomposites promote angiogenic diabetic wound repair through reconstructing high Glucose-Derived immune Inhibition. ACS Nano. 2024;18(5):4269\u201386.","journal-title":"ACS Nano"},{"issue":"1","key":"3330_CR32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s13402-019-00476-6","volume":"43","author":"Z Yang","year":"2020","unstructured":"Yang Z, et al. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210. Cell Oncol (Dordr). 2020;43(1):123\u201336.","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"3330_CR33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13046-025-03272-3","volume":"44","author":"H Wang","year":"2025","unstructured":"Wang H, et al. AGD1\/USP10\/METTL13 complexes enhance cancer stem cells proliferation and diminish the therapeutic effect of docetaxel via CD44 m6A modification in castration resistant prostate cancer. J Exp Clin Cancer Res. 2025;44(1):12.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"3330_CR34","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1038\/s41375-023-01896-y","volume":"37","author":"F Cheng","year":"2023","unstructured":"Cheng F, et al. Osteocyte-derived exosomes confer multiple myeloma resistance to chemotherapy through acquisition of cancer stem cell-like features. Leukemia. 2023;37(6):1392\u20136.","journal-title":"Leukemia"},{"issue":"44","key":"3330_CR35","doi-asserted-by":"publisher","first-page":"e2402600","DOI":"10.1002\/advs.202402600","volume":"11","author":"C Yang","year":"2024","unstructured":"Yang C, et al. LncRNA-Mediated TPI1 and PKM2 promote Self-Renewal and chemoresistance in GBM. Adv Sci (Weinh). 2024;11(44):e2402600.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"3330_CR36","doi-asserted-by":"publisher","first-page":"p206","DOI":"10.1186\/s13046-024-03134-4","volume":"43","author":"Z Lin","year":"2024","unstructured":"Lin Z, et al. m(6)A-mediated lnc-OXAR promotes oxaliplatin resistance by enhancing Ku70 stability in non-alcoholic steatohepatitis-related hepatocellular carcinoma. J Exp Clin Cancer Res. 2024;43(1):p206.","journal-title":"J Exp Clin Cancer Res"},{"key":"3330_CR37","doi-asserted-by":"publisher","first-page":"101111","DOI":"10.1016\/j.drup.2024.101111","volume":"76","author":"KL Chen","year":"2024","unstructured":"Chen KL, et al. LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein. Drug Resist Updat. 2024;76:101111.","journal-title":"Drug Resist Updat"},{"key":"3330_CR38","doi-asserted-by":"publisher","first-page":"101058","DOI":"10.1016\/j.drup.2024.101058","volume":"73","author":"KKW To","year":"2024","unstructured":"To KKW, et al. Utilizing non-coding RNA-mediated regulation of ATP binding cassette (ABC) transporters to overcome multidrug resistance to cancer chemotherapy. Drug Resist Updat. 2024;73:101058.","journal-title":"Drug Resist Updat"},{"key":"3330_CR39","doi-asserted-by":"publisher","first-page":"217398","DOI":"10.1016\/j.canlet.2024.217398","volume":"611","author":"J Yuan","year":"2024","unstructured":"Yuan J, et al. LncRNA FIRRE drives gastric cancer progression via ZFP64-mediated TUBB3 promoter activation. Cancer Lett. 2024;611:217398.","journal-title":"Cancer Lett"},{"issue":"12","key":"3330_CR40","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/s41419-024-07278-1","volume":"15","author":"Y Zhong","year":"2024","unstructured":"Zhong Y, et al. LOC730101 improves ovarian cancer drug sensitivity by inhibiting autophagy-mediated DNA damage repair via BECN1. Cell Death Dis. 2024;15(12):893.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3330_CR41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41392-020-00300-w","volume":"5","author":"H Song","year":"2020","unstructured":"Song H, et al. Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. Signal Transduct Target Ther. 2020;5(1):193.","journal-title":"Signal Transduct Target Ther"},{"key":"3330_CR42","doi-asserted-by":"crossref","unstructured":"Hou YR et al. The conserved LncRNA DIO3OS restricts hepatocellular carcinoma stemness by interfering with NONO-Mediated nuclear export of ZEB1 mRNA. Adv Sci (Weinh), 2023: p. e2301983.","DOI":"10.1002\/advs.202301983"},{"issue":"24","key":"3330_CR43","doi-asserted-by":"publisher","first-page":"e2307639","DOI":"10.1002\/advs.202307639","volume":"11","author":"T Jin","year":"2024","unstructured":"Jin T, et al. HnRNPA2B1 isgylation regulates m6A-Tagged mRNA selective export via ALYREF\/NXF1 complex to foster breast Cancer development. Adv Sci (Weinh). 2024;11(24):e2307639.","journal-title":"Adv Sci (Weinh)"},{"issue":"17","key":"3330_CR44","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.scib.2021.01.027","volume":"66","author":"L Xiang","year":"2021","unstructured":"Xiang L, et al. MAFG-AS1\/MAFG positive feedback loop contributes to cisplatin resistance in bladder urothelial carcinoma through antagonistic ferroptosis. Sci Bull (Beijing). 2021;66(17):1773\u201388.","journal-title":"Sci Bull (Beijing)"},{"issue":"1","key":"3330_CR45","doi-asserted-by":"publisher","first-page":"6348","DOI":"10.1038\/s41467-020-20165-5","volume":"11","author":"S Agarwal","year":"2020","unstructured":"Agarwal S, et al. The long non-coding RNA LUCAT1 is a negative feedback regulator of interferon responses in humans. Nat Commun. 2020;11(1):6348.","journal-title":"Nat Commun"},{"issue":"8","key":"3330_CR46","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1093\/neuonc\/noae036","volume":"26","author":"H Huang","year":"2024","unstructured":"Huang H, et al. Long non-coding RNA lung cancer-associated transcript-1 promotes glioblastoma progression by enhancing Hypoxia-inducible factor 1 alpha activity. Neuro Oncol. 2024;26(8):1388\u2013401.","journal-title":"Neuro Oncol"},{"issue":"10","key":"3330_CR47","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41419-020-03095-4","volume":"11","author":"R Wu","year":"2020","unstructured":"Wu R, et al. The long noncoding RNA LUCAT1 promotes colorectal cancer cell proliferation by antagonizing nucleolin to regulate MYC expression. Cell Death Dis. 2020;11(10):908.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3330_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12943-019-1122-z","volume":"19","author":"L Huan","year":"2020","unstructured":"Huan L, et al. Hypoxia induced LUCAT1\/PTBP1 axis modulates cancer cell viability and chemotherapy response. Mol Cancer. 2020;19(1):11.","journal-title":"Mol Cancer"},{"issue":"1","key":"3330_CR49","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s13046-019-1315-8","volume":"38","author":"A Zheng","year":"2019","unstructured":"Zheng A, et al. Long non-coding RNA LUCAT1\/miR-5582-3p\/TCF7L2 axis regulates breast cancer stemness via Wnt\/beta-catenin pathway. J Exp Clin Cancer Res. 2019;38(1):305.","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"3330_CR50","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41568-024-00706-6","volume":"24","author":"R Polak","year":"2024","unstructured":"Polak R, Zhang ET, Kuo CJ. Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment. Nat Rev Cancer. 2024;24(8):523\u201339.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"3330_CR51","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41563-021-01057-5","volume":"21","author":"BL LeSavage","year":"2022","unstructured":"LeSavage BL, et al. Next-generation cancer organoids. Nat Mater. 2022;21(2):143\u201359.","journal-title":"Nat Mater"},{"issue":"9","key":"3330_CR52","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.ccell.2021.07.020","volume":"39","author":"V Veninga","year":"2021","unstructured":"Veninga V, Voest EE. Tumor organoids: opportunities and challenges to guide precision medicine. Cancer Cell. 2021;39(9):1190\u2013201.","journal-title":"Cancer Cell"},{"issue":"2","key":"3330_CR53","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","volume":"173","author":"SH Lee","year":"2018","unstructured":"Lee SH, et al. Tumor evolution and drug response in Patient-Derived organoid models of bladder Cancer. Cell. 2018;173(2):515\u2013e52817.","journal-title":"Cell"},{"issue":"4","key":"3330_CR54","doi-asserted-by":"publisher","first-page":"e2103999","DOI":"10.1002\/advs.202103999","volume":"9","author":"Z Li","year":"2022","unstructured":"Li Z, et al. Patient-Derived upper tract urothelial carcinoma organoids as a platform for drug screening. Adv Sci (Weinh). 2022;9(4):e2103999.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"3330_CR55","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","volume":"81","author":"R Cathomas","year":"2022","unstructured":"Cathomas R, et al. The 2021 updated European association of urology guidelines on metastatic urothelial carcinoma. Eur Urol. 2022;81(1):95\u2013103.","journal-title":"Eur Urol"},{"issue":"2","key":"3330_CR56","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.eururo.2021.03.014","volume":"80","author":"A Necchi","year":"2021","unstructured":"Necchi A, et al. Molecular characterization of residual bladder Cancer after neoadjuvant pembrolizumab. Eur Urol. 2021;80(2):149\u201359.","journal-title":"Eur Urol"},{"issue":"7","key":"3330_CR57","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/S1470-2045(21)00284-9","volume":"22","author":"ZB Zengin","year":"2021","unstructured":"Zengin ZB, et al. Chemoimmunotherapy in urothelial cancer: concurrent or sequential? Lancet Oncol. 2021;22(7):894\u20136.","journal-title":"Lancet Oncol"},{"issue":"5","key":"3330_CR58","doi-asserted-by":"publisher","first-page":"e2408599","DOI":"10.1002\/advs.202408599","volume":"12","author":"M Deng","year":"2025","unstructured":"Deng M, et al. Enhanced oxidative phosphorylation driven by TACO1 mitochondrial translocation promotes stemness and cisplatin resistance in bladder Cancer. Adv Sci (Weinh). 2025;12(5):e2408599.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"3330_CR59","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13046-024-03254-x","volume":"44","author":"W Hu","year":"2025","unstructured":"Hu W, et al. CYP3A5 promotes glioblastoma stemness and chemoresistance through fine-tuning NAD(+)\/NADH ratio. J Exp Clin Cancer Res. 2025;44(1):3.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"3330_CR60","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.eururo.2024.05.026","volume":"86","author":"NM Merrill","year":"2024","unstructured":"Merrill NM, et al. Integrative drug screening and multiomic characterization of Patient-derived bladder Cancer organoids reveal novel molecular correlates of gemcitabine response. Eur Urol. 2024;86(5):434\u201344.","journal-title":"Eur Urol"},{"issue":"42","key":"3330_CR61","doi-asserted-by":"publisher","first-page":"6081","DOI":"10.1038\/s41388-021-01999-9","volume":"40","author":"P Tan","year":"2021","unstructured":"Tan P, et al. SRT1720 inhibits the growth of bladder cancer in organoids and murine models through the SIRT1-HIF axis. Oncogene. 2021;40(42):6081\u201392.","journal-title":"Oncogene"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03330-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03330-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03330-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T14:02:21Z","timestamp":1741010541000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03330-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3330"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03330-w","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of The First Affiliated Hospital of Zhengzhou University and The First Affiliated Hospital of Shenzhen University, and written informed consents were obtained before any operation to patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors confirm that we obtained written consent from the patients to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}